RSV: 81 ADVERSE Reactions PER Each PREVENTED Case

… a proposed immunization against RSV, one of the viruses causing colds in adults

… mRNA-1345 vaccine (17,793)

… placebo (17,748)

… The placebo was saline

… Moderna proudly reported that its RSV vaccine prevented 66 cases of RSV in 17 thousand vaccinated people  [ Appendix, Table S8 ]

… vaccine efficacy of just 68% was relatively meager, far worse than the much-ballyhooed “95% efficacy” of COVID vaccines

… it caused 5,337 more adverse events in the vaccine group than in the placebo group  [ Appendix, Table S11 ]

… ranging from trivial, such as minor headaches, to more disturbing ones, such as underarm lymph node swelling, fevers, vomiting, etc.

… there were 81 adverse events per each prevented case of RSV

… 81 adverse events per case of RSV, essentially a mild cold

… to prevent about 17 worse-than-usual cases of RSV involving fevers, the vaccinated subgroup had to suffer through 267 vaccine-caused fevers  [ Appendix, Page 53 ]

… Similarly, to prevent all 66 cases of RSV, avoided in the vaccinated subgroup, the vaccinees had to suffer through 267 fevers caused by the RSV vaccine

… More worryingly, the mRNA RSV vaccine caused a whopping 1,620 cases of “underarm swelling” in axillary lymph nodes  [ Appendix, Page 52 ]

… 120 long-term axillary swellings, compared to only 49 in the unvaccinated subgroup

… how did a massive 1,091 of the “saline placebo” patients end up with underarm swelling?!

1,091 = 6.17%

… My answer: Moderna trial participants are mRNA vaccine fanatics and most likely took COVID boosters in addition to the RSV vaccine

… That explains why the “placebo” group had so much lymph node swelling, as well as other adverse events

… Why would mRNA-vaccinated subjects have more pneumonia?  [ Appendix, Table S14 ]

… Does all that make the proposed mRNA RSV vaccine safe and effective? Is there a “positive risk-benefit balance”?

[ The mRNA-1345 vaccine (Moderna) uses the same preF antigen and is based on the mRNA vaccine platform that was previously shown to be effective in addressing the worldwide burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The mRNA-1345 vac- cine is a lipid nanoparticle–encapsulated mRNA- based vaccine encoding the membrane-anchored RSV-F glycoprotein, derived from an RSV A strain, and stabilized in the preF conformation – New England J M, Page 2 (2234) ] 

                Igor Chudov

                New England J M